PT-141 / Bremelanotide
Melanocortin receptor agonist. The medicine bremelanotide has a specific clinical indication.
Search names: Bremelanotide, Vyleesi
Evidence
Catalogue entry · see sources
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: 2.7 hours
Human information in catalogueContext and sources for the statistics reference
After subcutaneous administration; reported range 1.9–4.0 hours.
2.7 hours · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · PT-141 ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Adverse effects are not fully mapped in this entry. Consult the sources for the specific compound and use.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Find researchPubMed · PT-141 / Bremelanotide↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.